Moreover, trials such as ILLUMINATE have evaluated tabalumab, displaying biological activity consistent with BAFF inhibition, yet failing to demonstrate significant clinical efficacy in treating SLE (178). Here, TNFSF13B is linked to systemic lupus erythematosus.